Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies
Top Cited Papers
- 1 January 2006
- journal article
- hematologic malignancies
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (1) , 166-173
- https://doi.org/10.1200/jco.2005.01.9679
Abstract
Purpose To document the toxicity and activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with pretreated hematologic malignancies. Patients and Methods ...Keywords
This publication has 16 references indexed in Scilit:
- Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphomaBlood, 2003
- Acetylation inactivates the transcriptional repressor BCL6Nature Genetics, 2002
- The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: Implications for a role of BCL6 in the down-regulation of apoptosisProceedings of the National Academy of Sciences, 2002
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001
- Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed CellsJNCI Journal of the National Cancer Institute, 2000
- BCL-6 Represses Genes that Function in Lymphocyte Differentiation, Inflammation, and Cell Cycle ControlImmunity, 2000
- Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitorsNature, 1999
- Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of an Inhibitor of Histone DeacetylaseJNCI Journal of the National Cancer Institute, 1998
- A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylasesProceedings of the National Academy of Sciences, 1998